dennis mccain
  • Home
  • Investing
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options

Investing

Ideas and Strategies on Investing.

Previous Articles

Manipulating the Genome

9/19/2017

0 Comments

 
As most will agree, the search for the medical cures of tomorrow will ultimately be found inside the Human Genome. And those cures will be treated by editing the gene sequences to eliminate the defective sequences. We're only now scratching the surface of this relatively new technology and there'll be both corporate winners and losers in the years ahead. Today I want to look at three gene editing companies that are on the cutting edge of this movement and could be the big winners in this nascent scientific endeavor.
​
 

​Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
(Summary) (Company) (Chart)
17 September 2017
Price $20.94
1yr Target $35.25
Analysts 6
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 68.33%
Yield 0.00%
1yr Tot Return 68.33%

P/E ---
PEG ---
Beta ---


EPS (ttm) $-3.19
EPS next yr $-2.85
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $876.55 Mil
Revenues $5.60 Mil
Earnings $-117.90 Mil
Profit Margin ---

Quick Ratio 6.70
Current Ratio 6.70
Debt/Equity 0.26


1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -38.20%
ROE -67.80%


Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. Intellia Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
(Summary) (Company) (Chart)
17 September 2017
Price $22.68
1yr Target $27.17
Analysts 6
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 19.79%
Yield 0.00%
1yr Tot Return 19.79%

P/E ---
PEG ---
Beta ---
EPS (ttm) $-1.33
EPS next yr $-2.06
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $794.93 Mil
Revenues $22.60 Mil
Earnings $-46.30 Mil
Profit Margin ---

Quick Ratio 9.30
Current Ratio 9.30
Debt/Equity 0.00
1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -16.20 
ROE -22.70%
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
​(Summary) (Company) (Chart)
17 September 2017
Price $19.19
1yr Target $23.80
Analysts 5
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 24.02%
Yield 0.00%
1yr Tot Return 24.02%

P/E ---
PEG ---
Beta ---
​
EPS (ttm) $-0.07
EPS next yr $-3.02
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $793.89 Mil
Revenues $10.20 Mil
Earnings $-41.40 Mil
Profit Margin ---

Quick Ratio 17.80
Current Ratio 17.80
Debt/Equity 0.00
1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR --- 

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -13.20%
ROE -28.40%
Picture

My Path Forward

This really is the future of BioTechnology and to not have a stake in it is just crazy. These may not be the eventual winners but this early in the development of this science it's prudent to be in the game. So my path forward, based on my limited knowledge of gene editing limited to a few college courses, is to buy a small position in all three companies. This is based on the fact that all three companies are tied in with, and partnered with, some large capitalization pharma companies that have the financial backing to push this forward. 

​I expect to get a lot of my investing intelligence from the daily, weekly and monthly charts. I will be watching the price and volume movements to determine what other investors and traders are buying and selling. That may seem like simply following the crowd, and in many ways it is, I'll be watching the momentum indicators to try to anticipate moves both up and down. I'll also rely on earnings expectations and announcements to look for changes from quarter to quarter and year to year.

Over time I should be able to determine the winners and losers. And the winners are the ones I'll be increasingly adding to my portfolio.


0 Comments



Leave a Reply.

    Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

    Picture

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.


    RSS Feed


    Picture
    Top 100 Blogs for Dividend Investors

    Picture
    Follow Me on StockTwits!



    Dividend Growth Stocks
    Dividend Growth Investor


    Picture
    I'm on Seeking Alpha too!

    Archives

    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013


    ADDITIONAL RESOURCES:
    4 Month INDU Chart
    Dividend Ex-Dates
    Bidness Etc
    SharpCharts Voyeur
    StockCharts.com

    FINVIZ
    Seeking Alpha
    BDC Reporter
    Roadmap2Retire
    DivHut
    Dividend Growth Investor

    Dividend Yield

    Stock Market Mentor
    Chart Swing Trader
    Dividend Announcements
    IBD TV
    Stocks to Watch Today
    Dividend Detective

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Picture
Powered by Create your own unique website with customizable templates.